Urine drug test may boost adherence to blood pressure medications
The largest ever UK trial of a urine test used across the NHS to spot when patients skip their medication has shown it may improve adherence to treatment.
The National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) is the largest BRC outside the South East of England and the beating heart of translational research across Greater Manchester, Lancashire and South Cumbria, transforming scientific breakthroughs into diagnostic tests and life-saving treatments for patients.
Awarded £64.1 million (2022-28) – the largest single research award given by the NIHR to the city region – Manchester BRC brings together world-leading researchers based at The University of Manchester and six of the country’s foremost NHS Trusts, with a vision to drive health improvements and lasting change for all through creative, inclusive and proactive research that identifies and bridges gaps between new discoveries and individualised care.
Manchester BRC is driving forward pioneering research in the areas of cancer (prevention and early detection, advanced radiotherapy, precision medicine, living with and beyond cancer), inflammation (rheumatic and musculoskeletal disease, respiratory medicine, dermatology, integrative cardiovascular medicine), under-researched conditions (hearing health, mental health, rare conditions) and advanced diagnostics and therapeutics (next generation phenotyping and diagnostics, next generation therapeutics).
Improving health across the city regionThe largest ever UK trial of a urine test used across the NHS to spot when patients skip their medication has shown it may improve adherence to treatment.
Advances in artificial intelligence (AI) may enable routine eye tests of the future to detect early signs of heart and brain disease long before symptoms appear.
Research is vital to help us understand more about a particular disease or condition and how to treat them.
Help shape our research plans
We’re looking to build collaborations with industry, public and charity partners to deliver on our ambitious plans.
The development of new clinical tests and treatments requires significant investment, specialist facilities and a diverse skillset, only made possible through a collaborative approach.
Read more about our partnerships